751 related articles for article (PubMed ID: 19110267)
1. Effect of tamsulosin on systemic blood pressure and nonneurogenic dysfunctional voiding in children.
Vanderbrink BA; Gitlin J; Toro S; Palmer LS
J Urol; 2009 Feb; 181(2):817-22; discussion 822. PubMed ID: 19110267
[TBL] [Abstract][Full Text] [Related]
2. Primary bladder neck dysfunction in children and adolescents II: results of treatment with alpha-adrenergic antagonists.
Donohoe JM; Combs AJ; Glassberg KI
J Urol; 2005 Jan; 173(1):212-6. PubMed ID: 15592078
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A in combination with standard urotherapy for children with dysfunctional voiding.
Petronijevic V; Lazovic M; Vlajkovic M; Slavkovic A; Golubovic E; Miljkovic P
J Urol; 2007 Dec; 178(6):2599-602; discussion 2602-3. PubMed ID: 17945299
[TBL] [Abstract][Full Text] [Related]
5. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
6. The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children.
Franco I; Landau-Dyer L; Isom-Batz G; Collett T; Reda EF
J Urol; 2007 Oct; 178(4 Pt 2):1775-9; discussion 1779-80. PubMed ID: 17707430
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
8. Intermittent tamsulosin therapy in men with lower urinary tract symptoms.
Yanardag H; Goktas S; Kibar Y; Kilic S; Erduran D
J Urol; 2005 Jan; 173(1):155-7. PubMed ID: 15592062
[TBL] [Abstract][Full Text] [Related]
9. Primary bladder neck dysfunction in children and adolescents III: results of long-term alpha-blocker therapy.
Van Batavia JP; Combs AJ; Horowitz M; Glassberg KI
J Urol; 2010 Feb; 183(2):724-30. PubMed ID: 20022041
[TBL] [Abstract][Full Text] [Related]
10. Double-blind placebo controlled study of alpha-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population.
Kramer SA; Rathbun SR; Elkins D; Karnes RJ; Husmann DA
J Urol; 2005 Jun; 173(6):2121-4; discussion 2124. PubMed ID: 15879863
[TBL] [Abstract][Full Text] [Related]
11. α1-Blockers for the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a prospective randomized study.
Minardi D; Pellegrinelli F; Conti A; Fontana D; Mattia M; Milanese G; Muzzonigro G
Int J Urol; 2015 Jan; 22(1):115-21. PubMed ID: 25141907
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of tamsulosin in treating women with voiding difficulty.
Chang SJ; Chiang IN; Yu HJ
Int J Urol; 2008 Oct; 15(11):981-5. PubMed ID: 18721208
[TBL] [Abstract][Full Text] [Related]
13. [The comparative study on selective alpha1-blocker and behavioural therapy in the treatment of discoordinated voiding in children].
Kroll P; Jankowski A; Maćkowiak J
Przegl Lek; 2006; 63 Suppl 3():226-8. PubMed ID: 16898538
[TBL] [Abstract][Full Text] [Related]
14. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia.
Schulman CC; Lock TM; Buzelin JM; Boeminghaus F; Stephenson TP; Talja M;
J Urol; 2001 Oct; 166(4):1358-63. PubMed ID: 11547074
[TBL] [Abstract][Full Text] [Related]
15. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
[TBL] [Abstract][Full Text] [Related]
16. The effects of bladder over distention on voiding function in kindergarteners.
Yang SS; Chang SJ
J Urol; 2008 Nov; 180(5):2177-82; discussion 2182. PubMed ID: 18804816
[TBL] [Abstract][Full Text] [Related]
17. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
18. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
[TBL] [Abstract][Full Text] [Related]
19. Open-label, longitudinal study of tamsulosin for functional bladder outlet obstruction in women.
Costantini E; Lazzeri M; Bini V; Zucchi A; Fioretti F; Frumenzio E; Porena M
Urol Int; 2009; 83(3):311-5. PubMed ID: 19829032
[TBL] [Abstract][Full Text] [Related]
20. Results of treatment with tamsulosin in men with acute urinary retention.
Kim HL; Kim JC; Benson DA; Bales GT; Gerber GS
Tech Urol; 2001 Dec; 7(4):256-60. PubMed ID: 11763483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
